Cara Therapeutics (CARA) Revenue & Revenue Breakdown
Cara Therapeutics Revenue Highlights
Latest Revenue (Y)
$20.97M
Latest Revenue (Q)
$2.56M
Main Segment (Y)
Other Revenue
Cara Therapeutics Revenue by Period
Cara Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $20.97M | -49.92% |
| 2022-12-31 | $41.87M | 81.81% |
| 2021-12-31 | $23.03M | -82.95% |
| 2020-12-31 | $135.08M | 579.28% |
| 2019-12-31 | $19.89M | 47.64% |
| 2018-12-31 | $13.47M | 1378.49% |
| 2017-12-31 | $911.00K | 959.30% |
| 2016-12-31 | $86.00K | -97.74% |
| 2015-12-31 | $3.80M | 19.70% |
| 2014-12-31 | $3.18M | -73.45% |
| 2013-12-31 | $11.96M | 905.38% |
| 2012-12-31 | $1.19M | 100.00% |
| 2011-12-31 | - | - |
Cara Therapeutics generated $20.97M in revenue during NA 2023, up -49.92% compared to the previous quarter, and up 155.68% compared to the same period a year ago.
Cara Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $2.56M | 157.92% |
| 2024-06-30 | $991.00K | -53.58% |
| 2024-03-31 | $2.13M | -28.93% |
| 2023-12-31 | $3.00M | -38.27% |
| 2023-09-30 | $4.87M | -29.81% |
| 2023-06-30 | $6.93M | 12.46% |
| 2023-03-31 | $6.17M | 89.05% |
| 2022-12-31 | $3.26M | -69.84% |
| 2022-09-30 | $10.81M | -52.99% |
| 2022-06-30 | $23.00M | 380.23% |
| 2022-03-31 | $4.79M | 483.43% |
| 2021-12-31 | $821.00K | -95.95% |
| 2021-09-30 | $20.27M | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2021-03-31 | $1.94M | -98.27% |
| 2020-12-31 | $112.09M | 1109.68% |
| 2020-09-30 | $9.27M | 64.47% |
| 2020-06-30 | $5.63M | -30.38% |
| 2020-03-31 | $8.09M | 79.41% |
| 2019-12-31 | $4.51M | -22.02% |
| 2019-09-30 | $5.79M | 11.08% |
| 2019-06-30 | $5.21M | 18.85% |
| 2019-03-31 | $4.38M | -20.80% |
| 2018-12-31 | $5.53M | 9.30% |
| 2018-09-30 | $5.06M | 76.13% |
| 2018-06-30 | $2.87M | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | -100.00% |
| 2017-03-31 | $911.00K | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | -100.00% |
| 2016-06-30 | $79.00K | 1028.57% |
| 2016-03-31 | $7.00K | 100.00% |
| 2015-12-31 | - | -100.00% |
| 2015-09-30 | $2.44M | 179.18% |
| 2015-06-30 | $874.00K | 78.73% |
| 2015-03-31 | $489.00K | -46.50% |
| 2014-12-31 | $914.00K | -18.76% |
| 2014-09-30 | $1.13M | 17.19% |
| 2014-06-30 | $960.00K | 439.33% |
| 2014-03-31 | $178.00K | -81.71% |
| 2013-12-31 | $973.00K | -4.42% |
| 2013-09-30 | $1.02M | -89.79% |
| 2013-06-30 | $9.97M | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | - |
Cara Therapeutics generated $2.56M in revenue during Q3 2024, up 157.92% compared to the previous quarter, and up 36.87% compared to the same period a year ago.
Cara Therapeutics Revenue Breakdown
Cara Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 18 |
|---|---|---|
| Other Revenue | $699.00K | - |
| License And Milestone Fees | - | $13.44M |
Cara Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Other Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Commercial supply revenue | $640.00K | $640.00K | $640.00K | - | - |
| Other revenue | $1.26M | - | - | - | - |
| Collaborative revenue | $1.30M | $788.00K | $788.00K | - | - |
| Other Revenue | - | $991.00K | $623.00K | - | - |
| Commercial Supply Revenue | - | - | - | $2.06M | $4.79M |
| Commercial Supply Revenue With Associated Costs Of Goods Sold | - | - | - | - | $2.50M |
Cara Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Collaborative revenue (40.61%), Other revenue (39.36%), and Commercial supply revenue (20.03%).
Cara Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Dec 22 | Mar 22 |
|---|---|---|
| Commercial Supply Revenue | $2.06M | $4.79M |
| Commercial Supply Revenue With Associated Costs Of Goods Sold | - | $2.50M |
Cara Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 22: Commercial Supply Revenue (100.00%).